

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Thonnard, et al.

Docket No.: BM45417

Serial No.: Unknown

Filed: Herewith

For: Novel Compounds

Group Art Unit No.: Unknown

Examiner: Unknown

PRELIMINARY AMENDMENT

Sir:

Applicant respectfully requests that this Preliminary Amendment be entered in this case before the calculation of fees and before examination of the subject application.

In the Specification:

On page 1, please insert as the first paragraph of this application (after the title):

--This application is a National Phase Application of WO 01/19862, and claims priority of GB 9923156.5; filed 30 September 1999.--

In the Claims:

Please delete the claims of the application as filed in the PCT and substitute therefor: .

27. An isolated polypeptide comprising a member selected from the group consisting of

- (a) an amino acid sequence matching SEQ ID NO:2 or SEQ ID NO:4 or SEQ ID NO:6 and

- (b) an immunogenic polypeptide comprising a fragment sequence of at least 15 amino acids that matches an aligned contiguous segment of SEQ ID NO:2 or SEQ ID NO:4, or SEQ ID NO:6,

wherein the isolated polypeptide, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell immune response to a polypeptide having the sequence of SEQ ID NO:2 or SEQ ID NO:4 or SEQ ID NO:6.

28. An isolated polynucleotide encoding a polypeptide of Claim 27 or the full complement to the isolated polynucleotide.

29. The isolated polypeptide of claim 27, wherein the polypeptide is according to (a).